OncoMatch/Clinical Trials/NCT04268199
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Is NCT04268199 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Bortezomib for myeloma.
Treatment: Bortezomib — This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Multiple Myeloma
Prior therapy
Must have received: proteasome inhibitor (bortezomib) — hospital and/or cancer centre environment
Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04268199 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages